Mar-Cof Bp (brompheniramine maleate/pseudoephedrine HCl/codeine phosphat)
Last reviewed · Source: First Databank (FDB) drug data
Overview
Brompheniramine and dexbrompheniramine are alkylamine (propylamine)-derivative first generation antihistamines.
Pseudoephedrine is a sympathomimetic agent that occurs naturally in plants of the genus Ephedra; the drug acts directly on both alpha- and, to a lesser degree, beta-adrenergic receptors.
Brompheniramine and dexbrompheniramine share the actions and uses of other antihistamines. Preparations containing brompheniramine maleate or dexbrompheniramine maleate in fixed combination with other agents (e.g., dextromethorphan, guaifenesin, phenylephrine, pseudoephedrine) are used for relief of rhinorrhea, sneezing, lacrimation, itching eyes, oronasopharyngeal itching, and/or other symptoms (e.g., nasal/sinus congestion, cough) associated with allergic rhinitis (e.g., hay fever), other upper respiratory allergies, or the common cold. Combination preparations generally should only be used when symptoms amenable to each ingredient are present concurrently.
Generic name: brompheniramine maleate/pseudoephedrine HCl/codeine phosphat
Reference product & biosimilars
No reference, biosimilar or interchangeable associated with this drug.
Today’s intelligence on Mar-Cof Bp
Indications
The following indications are listed for Mar-Cof Bp:
- Allergic Rhinitis
- Cold Symptoms
- Cough
- Nasal Congestion
- Rhinorrhea
Also known as: Nasal Stuffiness.
Dosing
Dosage of brompheniramine maleate and dexbrompheniramine maleate is expressed in terms of the salt. Dosage of brompheniramine maleate and dexbrompheniramine maleate should be individualized according to the patient's response and tolerance.
Fixed-ratio combination preparations do not permit individual titration of dosages; if a fixed combination is used, the precautions and contraindications associated with each drug must be considered.
Brompheniramine maleate and dexbrompheniramine maleate are administered orally. These agents should be administered with food, water, or milk to minimize gastric irritation.
Doses of brompheniramine maleate oral solution should be measured using the measuring device (e.g., calibrated dropper, cup, spoon) provided by the manufacturer.
Pseudoephedrine hydrochloride and sulfate are administered orally.
Pseudoephedrine hydrochloride 240-mg extended-release tablets should be administered orally once daily and swallowed whole with water; the extended-release tablets should not be divided, crushed, chewed, or dissolved. Patients should be advised that the tablet does not completely dissolve and may be passed in the stool.
No dosing information is available for this tab.
No dosing information is available for this tab.
Drug interactions
There is no enhanced messaging for this drug.
There are no contraindication interactions for this drug.
There are no severe interactions for this drug.
There are no moderate interactions for this drug.
Contraindications
There is no enhanced messaging for this drug.
There are no contraindication contraindications for this drug.
There are no severe contraindications for this drug.
There are no moderate contraindications for this drug.
Adverse reactions
There is no enhanced messaging for this drug.
There are no severe adverse reactions for this drug.
There are no less severe adverse reactions for this drug.
Precautions
No enhanced messaging available.
No enhanced messaging available.
There is inadequate experience with use of brompheniramine or dexbrompheniramine in pregnant women to determine whether the potential for harm to the fetus exists. Because of the risk of severe reactions (e.g., seizures) to antihistamines in neonates, brompheniramine or dexbrompheniramine should not be used during the third trimester; the drugs should be used during the first 2 trimesters only when the potential benefits justify the possible risks to the fetus.
It is not known if brompheniramine is distributed into milk. Because of the potential for serious adverse reactions to antihistamines in nursing infants, a decision should be made whether to discontinue nursing or brompheniramine or dexbrompheniramine, taking into account the importance of the drug to the woman. Excessive crying, irritability, and sleep disturbances occurred in one breast-fed infant whose mother was receiving dexbrompheniramine combined with pseudoephedrine; normal behavior in the infant resumed within 12 hours after the mother discontinued the drug and the infant received 2 formula feedings.
No enhanced messaging available.
ICD codes
No ICD codes are available for this drug.
Formulary status
Search health-plan coverage for this drug by ZIP code.
Choose the first character of a health plan name.
Last reviewed · Source: First Databank (FDB) drug data
On this page
Actions
Sign in to save favorites
Saving this drug requires a free Physicians Office Resource account.